We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Alkermes’ Aristada Set to Join Generic Abilify Market
Alkermes’ Aristada Set to Join Generic Abilify Market
Alkermes is preparing to launch its schizophrenia drug Aristada in the U.S. following FDA approval Monday — making it the latest generic to threaten Otsuka’s grasp on the multibillion dollar antipsychotics market via Abilify.